Allozyne
company
About
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $3.50M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$33.50M
Allozyne has raised a total of
$33.50M
in funding over 2 rounds. Their latest funding was raised on
Oct 26, 2007 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 26, 2007 | Series B | $30M | 1 | — | — | Detail |
| Dec 6, 2005 | Series A | $3.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Allozyne is funded by 1 investors.
ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
